Milestone Scientific appoints Grassi & Co. as new auditor, dismisses CBIZ CPAs

Milestone Scientific Inc. (MLSS) has appointed Grassi & Co., CPAs, P.C. as its new independent registered public accounting firm, effective for the fiscal year ending December 31, 2026. This follows the dismissal of CBIZ CPAs P.C. as their auditor, a change approved by the company's Board of Directors. The previous auditor's report for 2025 indicated substantial doubt about Milestone Scientific's ability to continue as a going concern, though no disagreements on accounting principles or audit scope were reported.

Original reporting
Investing.com · Investing.com
Published May 6, 2026, 9:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 6, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Milestone Scientific appoints Grassi & Co. as new auditor, dismisses CBIZ CPAs — source image
Decision brief

The 30-second read

$MLSSNeutralMed
01

Why it matters

The auditor change could signal efforts to improve financial transparency or address previous concerns.

02

Market read

The news is relevant for short-term traders and investors monitoring MLSS stock volatility; long-term impact depends on subsequent financial disclosures.

03

What to watch

Potential positive developments in upcoming financial reports could offset initial concerns.

Relevance 6/10Timing: immediate; news published today

Background

Milestone Scientific has faced financial uncertainties, as evidenced by prior auditor's doubts about its going concern status.

Company-level read

Ticker impact

$MLSSNeutralMedium confidence
Context

The news pertains directly to Milestone Scientific's corporate governance and financial reporting, which can influence its stock price.

Expected impact

Potential short-term decline due to uncertainty, with possible stabilization if new auditor's report is positive.

Evidence & confidence

Changes in audit firms amid prior doubts about financial stability can cause investor concern, but the long-term impact depends on subsequent financial disclosures.

Market effects

Possible impact on healthcare and medical device sectors if investor sentiment shifts

Limited; primarily US-focused company

Low; company is not a major global player

Counterpoint

The auditor change might be a routine corporate governance update with minimal impact; the company's fundamentals remain strong.

Key entities

  • Milestone Scientific Inc.

    A medical device company specializing in dental and medical injection technologies.

  • Grassi & Co.

    The new independent registered public accounting firm appointed by MLSS.

  • CBIZ CPAs P.C.

    The previous auditor dismissed by MLSS.

Related articles

$VKTXMed

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026

Viking Therapeutics (VKTX) presented clinical data from its VK2735 obesity program at ObesityWeek 2026. In a Phase 2 trial, 74% of participants improved by at least one BMI category after 13 weeks, with significant reductions in cardiometabolic markers. The company also shared baseline data from its ongoing Phase 3 VANQUISH-2 study. VK2735 is a dual GLP-1 and GIP receptor agonist being developed for obesity and metabolic disorders.

$NVDAHigh

Jensen Huang steps down as Nvidia chief and the hunt for a new CEO begins

Nvidia announced CEO Jensen Huang's resignation and departure from the board. Colette Kress, the CFO, is interim CEO. The company thanked Huang for his contributions. No reason was given, but speculation links it to his personal scandal and national security concerns. The FBI is investigating alleged Nvidia chip exports to China via Megaspeed, where Alice Huang, tied to Jensen, is an executive. This could impact US-China relations and AI competition.

$NVDAHigh

The rise and fall of Jensen Huang

Nvidia's CEO Jensen Huang resigned after admitting an affair, with shares dropping 40% from October's peak. The board named CFO Colette Kress as interim CEO. Huang's exit raises concerns about Nvidia's key man risk and potential regulatory scrutiny, especially regarding US-China AI rivalry. The company's stock fell to $148.80 before recovering to $162.85.